Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
Earnings Data
Report Date
Feb 04, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
4.44Last Year’s EPS
3.45Same Quarter Last Year
Moderate Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance, significant revenue growth across multiple products, and promising pipeline advancements, particularly in the renal and CF segments. However, challenges remain with high gross to net impacts and some regulatory and development delays.Company Guidance
Revenue Growth
Vertex delivered $3.08 billion in revenue, reflecting double-digit growth versus Q3 2024, driven by strong performance across its portfolio.
ALYFTREK Expansion
ALYFTREK, which launched in the U.S. late last year, has shown strong uptake, especially among patients naive to CFTR modulators, with nearly 10x as many newly eligible patients in Europe compared to the U.S.
CASGEVY Revenue Milestone
CASGEVY is on track for over $100 million in revenue this year, with significant growth expected in 2026.
JOURNAVX Prescription Growth
More than 300,000 prescriptions for JOURNAVX have been filled as of mid-October, indicating strong market uptake.
Pipeline Progress
Vertex has several programs in Phase III development, including povetacicept for IgAN, which has received breakthrough therapy designation and is on track for potential accelerated approval.
Strong Financial Performance
Q3 2025 non-GAAP net income was $1.24 billion, a 10% increase from Q3 2024, with a non-GAAP earnings per share increase of 10%.
DE:VX1 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:VX1 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 03, 2025 | €366.55 | €366.40 | -0.04% |
Aug 06, 2025 | €333.45 | €323.25 | -3.06% |
May 05, 2025 | €444.45 | €389.30 | -12.41% |
Feb 10, 2025 | €455.75 | €446.40 | -2.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vertex Pharmaceuticals (DE:VX1) report earnings?
Vertex Pharmaceuticals (DE:VX1) is schdueled to report earning on Feb 04, 2026, After Close (Confirmed).
What is Vertex Pharmaceuticals (DE:VX1) earnings time?
Vertex Pharmaceuticals (DE:VX1) earnings time is at Feb 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Vertex Pharmaceuticals stock?
The P/E ratio of Vertex Pharmaceuticals is N/A.
What is DE:VX1 EPS forecast?
DE:VX1 EPS forecast for the fiscal quarter 2025 (Q4) is 4.44.